Drugs / Viralym-A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02276820 | Dec 2017 → Dec 2018 | adenoviridae infectious disease | AlloVir | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Viralym-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02276820 ↗ |
| Known as | AdV-specific T cells | “The AdV-specific T cells (Viralym-A) are an investigational product not approved by the Food and Drug Administration (FDA).” NCT02276820 ↗ |
| Modality | Cell therapy | “The AdV-specific T cells (Viralym-A) are an investigational product not approved by the Food and Drug Administration (FDA).” NCT02276820 ↗ |
| Route | Intravenous | “Partially HLA-matched Viralym-A cells will be thawed and given by intravenous injection.” NCT02276820 ↗ |